Anti-metastasis therapy: SMAD7 inhibits invasive motility via down regulation of ICAT (Inhibitor of β-catenin and TCF), 21/October/2014, 9.41 am

Anti-metastasis therapy: SMAD7 inhibits invasive motility via down regulation of ICAT (Inhibitor of β-catenin and TCF), 21/October/2014, 9.41 am

Anti-metastasis therapy: SMAD7 inhibits invasive motility via down regulation of ICAT (Inhibitor of β-catenin and TCF), 21/October/2014, 9.41 am 150 150

Idea Proposed/Formulated byDr L Boominathan Ph.D.

CitationBoominathan, L., Anti-metastasis therapy:  SMAD7 inhibits invasive motility via down regulation of ICAT (Inhibitor of β-catenin and TCF), 21/October/2014, 9.41 am, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org

Significance: This study suggests that SMAD7, by increasing the expression of its target gene, it may decrease the expression of EMT protein ICAT.  Therefore, pharmacological formulations encompassing “SMAD7 activators may be used to treat metastatic cancers.

Amount: $300

Undisclosed information: How SMAD7 decreases ICAT expression.

Web: http://genomediscovery.org

Courtesy: When you cite drop us a line at info@genomediscovery.org